Eli Lilly Issues Warning , About Fake Weight-Loss Drugs.
On June 20, Eli Lilly published an open letter,
warning about fake and compounded versions
of Mounjaro and Zepbound, ABC News reports. .
Lilly is committed to making life better
for people living with diabetes and
obesity through developing medicines
that change the way healthcare
providers can treat these diseases, Eli Lilly, via open letter.
Lilly Stands Against the Use of its
Medicines for Cosmetic Weight Loss, Eli Lilly, via open letter.
The company went on to advise consumers to stay away from buying weight-loss drugs online without a prescription. .
Lilly is deeply concerned about
the proliferation of online sales
and posts on social media involving
counterfeit, fake, compounded,
and any other unsafe or untested
versions of what they say is tirzepatide, Eli Lilly, via open letter.
Any products marketed simply as
“tirzepatide” (as opposed to
Mounjaro® and Zepbound®) were
not made by, studied by, or sold by
Lilly and are not FDA-approved. , Eli Lilly, via open letter.
Be aware that when you purchase
products that are not FDA-approved
medicines or obtain medicines from
an unverified source or without a prescription
from a licensed healthcare provider,
you may be purchasing fake, counterfeit,
or otherwise unsafe products. , Eli Lilly, via open letter.
Eli Lilly also addressed concerns about compounded medications.
Although compounding is legal amid
drug shortages, the FDA has shared
concerns about substandard products. .
Eli Lilly says that it has tested some compounded versions of its products,
only to find safety and efficacy issues.
Some products had high bacteria counts
and impurities, while others were
entirely different chemical structures.